Article citationsMore>>

Emery, P., Keystone, E., Tony, H.P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J. and Kremer, J. (2008) Il-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 67, 1516-1523. doi:10.1136/ard.2008.092932

has been cited by the following article:

• TITLE: Remission of arthritis but persistent cutaneous lesions following tocilizumab treatment in a RA-patient suffering from concomitant psoriasis

  AUTHORS: Wolfgang Hartung, Boris Ehrenstein, Rotraud Wallisch, Martin Fleck

  KEYWORDS: Tocilizumab; Rheumatoid Arthritis; Psoriasis; Treatment

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.2 No.1, March 25, 2013

  ABSTRACT: Modulation of the interleukin-6 pathway with tocilizumab has been demonstrated to be highly effective in substantial numbers of patients suffering from rheumatoid arthritis (RA), and juvenile idiopathic arthritis. A pivotal role of the IL-6 pathway has been also established in other autoimmune conditions including psoriasis and psoriatic arthritis, becoming attractive targets for therapeutic IL-6 inhibition. Here, we describe the first case of tocilizumab treatment in a RA-patient suffering from concomitant severe psoriasis, who achieved remission of RA, whereas no improvement of psoriatic lesions could be observed.